874 주식 개요
광저우 바이윈산 제약 홀딩스 유한회사는 자회사와 함께 중화인민공화국 및 국제적으로 중국 특허 및 서양 의약품, 화학 원료, 천연 및 생물학적 의약품, 화학 원료의 중간체를 연구, 개발, 제조 및 판매하고 있습니다. 자세한 내용
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited 경쟁사
가격 내역 및 성능
| 과거 주가 | |
|---|---|
| 현재 주가 | HK$17.70 |
| 52주 최고치 | HK$24.20 |
| 52주 최저치 | HK$16.62 |
| 베타 | 0.59 |
| 11개월 변경 | -7.23% |
| 3개월 변경 사항 | -7.81% |
| 1년 변경 사항 | -20.45% |
| 33년 변화 | -7.33% |
| 5년 변화 | -23.54% |
| IPO 이후 변화 | 1,220.90% |
최근 뉴스 및 업데이트
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26주주 수익률
| 874 | HK Healthcare | HK 마켓 | |
|---|---|---|---|
| 7D | -1.7% | -1.5% | -0.6% |
| 1Y | -20.4% | -27.6% | 9.6% |
수익률 대 산업: 874 지난 1년 동안 -27.6 %를 반환한 Hong Kong Healthcare 산업을 초과했습니다.
수익률 대 시장: 874 지난 1년 동안 9.6 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.
가격 변동성
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 6.2% |
| Healthcare Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
안정적인 주가: 874 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 874 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개
| 설립 | 직원 | CEO | 웹사이트 |
|---|---|---|---|
| 1997 | 28,760 | Hong Li | www.gybys.com.cn |
광저우 바이윈산 제약 홀딩스 유한회사는 자회사와 함께 중화인민공화국 및 국제적으로 중국 특허 및 서양 의약품, 화학 원료, 천연 및 생물 의약품, 화학 원료의 중간체를 연구, 개발, 제조, 판매하고 있습니다. 이 회사는 그레이트 서던 TCM, 그레이트 커머스, 그레이트 헬스 및 기타 부문을 통해 운영됩니다. 또한 서양 및 중국 의약품, 의료 기기, 의약품, 의료 장비 및 헬스케어 제품의 도매, 소매, 판매, 수입 및 수출, 음료, 식품, 헬스케어 제품 및 기타 제품의 연구 개발, 생산 및 판매, 사전 포장 식품, 유제품 등의 생산 및 판매, 허브 차, 정제, 캡슐, 로젠지, 거북이 허브 젤리 등의 제품도 제공합니다.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited 기본 사항 요약
| 874 기본 통계 | |
|---|---|
| 시가총액 | HK$46.40b |
| 수익(TTM) | HK$3.68b |
| 수익(TTM) | HK$82.05b |
7.8x
P/E 비율0.4x
P/S 비율874 주가가 과대평가되어 있나요?
공정 가치 및 가치 분석 보기수익 및 수익
| 874 손익 계산서(TTM) | |
|---|---|
| 수익 | CN¥76.39b |
| 수익 비용 | CN¥63.46b |
| 총 이익 | CN¥12.93b |
| 기타 비용 | CN¥9.50b |
| 수익 | CN¥3.42b |
최근 보고된 수익
Sep 30, 2024
다음 수익 날짜
n/a
| 주당 순이익(EPS) | 2.11 |
| 총 마진 | 16.92% |
| 순이익 마진 | 4.48% |
| 부채/자본 비율 | 35.5% |
874 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기